Aurinia Pharmaceuticals (NASDAQ: AUPH) revenue
Aurinia Pharmaceuticals reported revenue of $283.1m for fiscal 2025, 20.4% more than in fiscal 2024 ($235.1m). Since fiscal 2019 its revenue has grown by 88,911.0%, an average growth of 210.2% a year.
Aurinia Pharmaceuticals has grown its revenue for 4 years in a row, and fiscal 2025 is the highest of its 7 fiscal years on record. The biggest drop was in fiscal 2021, −9.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $283.1m | +20.4% | $104.9m | 37.1% |
| 2024 | $235.1m | +34.0% | −$4.7m | −2.0% |
| 2023 | $175.5m | +31.0% | −$91.7m | −52.2% |
| 2022 | $134.0m | +193.9% | −$111.5m | −83.2% |
| 2021 | $45.6m | −9.0% | −$180.7m | −396.3% |
| 2020 | $50.1m | +15,660.4% | −$104.3m | −208.1% |
| 2019 | $0.3m | — | −$90.9m | −28,598.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Aurinia Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Aurinia Pharmaceuticals ranks 224th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Aurinia Pharmaceuticals, 20.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 222nd | Rigel Pharmaceuticals | $294.3m | 64.1% |
| 223rd | Xeris Biopharma | $291.8m | 43.7% |
| 224th | Aurinia Pharmaceuticals | $283.1m | 20.4% |
| 225th | Adaptive Biotechnologies | $277.0m | 54.8% |
| 226th | Vericel | $276.3m | 16.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Aurinia Pharmaceuticals
- How much revenue did Aurinia Pharmaceuticals make in fiscal 2025?
- Aurinia Pharmaceuticals reported revenue of $283.1m for fiscal 2025, compared with $235.1m in fiscal 2024.
- How much has the revenue of Aurinia Pharmaceuticals grown?
- Between fiscal 2019 and fiscal 2025 it went from $0.3m to $283.1m: 88,911.0% more, an average growth of 210.2% a year.
- What was the best year for revenue at Aurinia Pharmaceuticals?
- Of its last 7 fiscal years, fiscal 2025, with $283.1m.
- Where does Aurinia Pharmaceuticals rank in its sector by revenue?
- It ranks 224th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Aurinia Pharmaceuticals come from?
- From the annual report (Form 10-K) that Aurinia Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Aurinia Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Aurinia Pharmaceuticals: the Aurinia Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.